within Pharmacolibrary.Drugs.ATC.A;

model A06AD61
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.03,
    Cl             = 0.016666666666666666,
    adminDuration  = 600,
    adminMass      = 0.02,
    adminCount     = 1,
    Vd             = 0.02,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0016666666666666668,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Lactulose is a synthetic disaccharide used primarily for the treatment of constipation and hepatic encephalopathy. In combination products, it can be formulated with other agents to enhance its laxative properties or treat related conditions. Lactulose is considered safe and is approved for use in many countries today.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters are estimated for healthy adults as no direct human PK publication is available for lactulose, combinations.</p><h4>References</h4><ol><li><p>Melichar, B, et al., &amp; Zadák, Z (2001). Intestinal permeability in patients with chemotherapy-induced stomatitis. <i>Journal of cancer research and clinical oncology</i> 127(5) 314–318. DOI:<a href=&quot;https://doi.org/10.1007/s004320000209&quot;>10.1007/s004320000209</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/11355146/&quot;>https://pubmed.ncbi.nlm.nih.gov/11355146</a></p></li><li><p>Melichar, B, et al., &amp; Tichá, A (2007). Gastrointestinal permeability in ovarian cancer and breast cancer patients treated with paclitaxel and platinum. <i>BMC cancer</i> 7 155–None. DOI:<a href=&quot;https://doi.org/10.1186/1471-2407-7-155&quot;>10.1186/1471-2407-7-155</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/17688683/&quot;>https://pubmed.ncbi.nlm.nih.gov/17688683</a></p></li><li><p>Zuckerman, MJ, et al., &amp; Hernandez, JA (2004). Assessment of intestinal permeability and absorption in cirrhotic patients with ascites using combined sugar probes. <i>Digestive diseases and sciences</i> 49(4) 621–626. DOI:<a href=&quot;https://doi.org/10.1023/b:ddas.0000026307.56909.21&quot;>10.1023/b:ddas.0000026307.56909.21</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/15185867/&quot;>https://pubmed.ncbi.nlm.nih.gov/15185867</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end A06AD61;
